CCR

CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.

BI-639667 is a potent and selective antagonist of human CCR1.

CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.

GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.

CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.

Nifeviroc is a CCR5 antagonist potentially for treatment of inflammatory responses to HIV type-1 infection